SPC
PVLA

Sigma Planning Corp’s Palvella Therapeutics PVLA Stock Holding History

Sigma Planning Corp’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,500
Closed -$680K – 1420
2025
Q4 		$680K Buy
+6,500
New +$554K 0.02% 683
2023
Q3 		– Sell
-326
Closed -$4.32K – 1310
2023
Q2 		$4.32K Sell
326
-4,055
-93% -$246K ﹤0.01% 1198
2023
Q1 		$342K Buy
4,381
+82
+2% +$9.5K 0.01% 953
2022
Q4 		$358K Buy
4,299
+354
+9% +$28.4K 0.01% 895
2022
Q3 		$363K Buy
3,945
+3
+0.1% +$387 0.01% 870
2022
Q2 		$590K Sell
3,942
-568
-13% -$104K 0.02% 692
2022
Q1 		$1.09M Buy
4,510
+20
+0.4% +$5.26K 0.03% 501
2021
Q4 		$1.36M Sell
4,490
-66
-1% -$21.1K 0.04% 429
2021
Q3 		$1.88M Buy
4,556
+58
+1% +$20.2K 0.06% 344
2021
Q2 		$1.38M Buy
4,498
+1,553
+53% +$341K 0.04% 441
2021
Q1 		$605K Buy
2,945
+46
+2% +$10.1K 0.02% 694
2020
Q4 		$580K Buy
2,899
+136
+5% +$28.3K 0.02% 641
2020
Q3 		$457K Buy
2,763
+494
+22% +$112K 0.02% 638
2020
Q2 		$563K Buy
2,269
+1,085
+92% +$254K 0.02% 554
2020
Q1 		$216K Buy
+1,184
New +$298K 0.01% 758

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sigma Planning Corp's PVLA Position: Q1 2026 in Review

Sigma Planning Corp sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 6,500 shares — an estimated $680K sold.

Sigma Planning Corp first reported a position in PVLA in Q1 2020 and held it in 15 quarters. The position peaked at $1.88M in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Sigma Planning Corp reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sigma Planning Corp sold 6,500 Palvella Therapeutics shares in Q1 2026, an estimated $680K.
  • Sigma Planning Corp first reported a position in Palvella Therapeutics in Q1 2020 and held it in 15 quarters.
  • Sigma Planning Corp's Palvella Therapeutics position peaked at $1.88M in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.